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Abstract: Antigen-presenting cells (APCs) play an important role in the development of autoimmune diseases. These 
cells recognize pathogen associated molecular patterns but also endogenously produced ligands through toll-like receptors 
(TLRs). Aberrant activation of these receptors and the following intracellular signaling pathways can induce the deleteri-
ous production of pro-inflammatory cytokines. In genetically predisposed individuals this might lead to a breach in toler-
ance and eventually autoimmunity. IgG and IgG immune complexes (ICs), which are abundantly present in autoimmune 
diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (SSc) are recognized 
by APCs via Fc gamma receptors (FcRs) and can also modulate their activation state. Upon their uptake specific antigens 
present in ICs are capable of stimulating APCs via their intracellular TLRs, increasing their capability to induce (autoreac-
tive) T and B cell responses. This underscores their likely role in the generation and maintenance of autoimmunity. By fo-
cusing on three autoimmune diseases, SLE, RA and SSc, we will illustrate the importance of TLRs and FcRs in the 
pathogenesis of autoimmune diseases.  
Keywords: Toll Like Receptors, Fc gamma receptors, Antigen-presenting cells, Systemic lupus erythematosus, Rheumatoid 
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INTRODUCTION 
 Most systemic autoimmune disorders, such as systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA) and 
systemic sclerosis (SSc) are diagnosed by the use of a set of 
defined classification criteria mirroring their phenotypic het-
erogeneity [1-3]. Variation in the underlying etiologic fac-
tors, such as environmental factors and the genetic back-
ground, seems to underlie this clinical complexity and phe-
notypic variability. A crucial etiologic factor seems to be the 
presence of specific antibodies aimed at endogenous ligands. 
Antibodies of the IgG type and IgG containing immune 
complexes (IC) are recognized by Fc gamma receptors 
(FcRs). These receptors are expressed by many kinds of 
immune cells including antigen-presenting cells (APCs) such 
as myeloid and plasmacytoid dendritic cells (DC), mono-
cytes and macrophages. The family of FcRs consists of the 
high affinity FcRI and the low affinity FcRIIa, IIb, IIc, IIIa 
and IIIb. FcRIIb is the only FcR with an immunoreceptor 
tyrosine-based inhibition motif (ITIM) instead of an activa-
tion motif (ITAM). IC binding to activating FcRs can in-
duce phagocytosis, antigen presentation, pro-inflammatory 
cytokine production and antibody-dependent cellular cyto-
toxicity. The simultaneous activation of the inhibitory 
FcRIIb inhibits these processes and can prevent the pro-
inflammatory actions caused by the activating receptors [4]. 
The resulting immune response upon the binding of IC thus 
depends on the balance between the activating and inhibitory 
FcRs. Activation of FcRIIa on monocyte-derived DCs re-
sults in DC maturation, increased stimulation of allogeneic T  
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cells, and enhanced secretion of inflammatory cytokines, 
while preferential activation of FcRIIb keeps DCs more 
immature, decreases the stimulation of allogeneic T cells and 
favors the development of Th2 responses even in the pres-
ence of a strong stimulus like lipopolysaccharide [4, 5].  
 It is widely recognized that a loss of immune tolerance to 
self components due to aberrant B and T cell reactivity is the 
shared basis of complex immune diseases such as SLE, RA 
and SSc. Type I interferons (IFNs) appear to play a crucial 
role in the breakdown of self tolerance. The finding that ap-
proximately 20% of patients treated with IFNs for various 
disorders develop an autoimmune disease underpins this 
notion [6]. IFNs are prototypically released by APCs, espe-
cially plasmacytoid DC (pDC), upon the activation of nu-
cleic acid sensing TLRs. TLRs are pattern recognition recep-
tors capable of recognizing both endogenous molecules re-
leased upon cell stress and a wide range of conserved con-
stituents from pathogens [7-9]. Four intracellular TLRs ca-
pable of sensing nucleic acids are found in APCs. TLR3 is 
activated by double stranded RNA (dsRNA), TLR7 and 
TLR8 by single stranded RNA (ssRNA) and TLR9 by un-
methylated CpG DNA. Another TLR known for its capabil-
ity to induce the release of IFNs is TLR4. TLR4 is expressed 
extracellular and recognizes lipopolysaccharides (LPS) from 
bacteria and a wide range of endogenous ligands [10]. An 
important part of its intracellular signaling cascade is shared 
with TLR3 explaining its capability of triggering IFN pro-
duction. TLRs are highly suspected as conductors of auto-
immunity [11]. The activation of multiple TLRs leads to the 
release of copious amounts of pro-inflammatory cytokines 
creating a volatile situation. In genetically predisposed indi-
viduals this might eventually lead to a breach in tolerance 
culminating in autoimmune disease [12]. The intracellular 
localization of the nucleic acid sensing TLRs prevents aber-
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rant activation of APCs by endogenous nucleic acids. In 
many autoimmune diseases however antibodies have been 
found aimed at nucleic acids or proteins bound to these, ena-
bling endocytosis of these ICs resulting in TLR activation by 
normally harmless components of self [13, 14]. This review 
focuses on FcR and TLR and their interplay in three proto-
typical autoimmune diseases, SLE, RA and SSc character-
ized by autoantibody production and likely mediated by an 
aberrant activation of TLR expressing APC.  
SYSTEMIC LUPUS ERYTHEMATOSUS 
 As a hallmark autoimmune disease SLE is a very hetero-
geneous disease. Individual patients vary in terms of the 
presence of specific auto-antibodies and the involvement of 
skin, kidneys, joints, the nervous system and other organs. 
The disease primarily affects women with a ratio of 9:1 
compared to males [15]. Excess formation of ICs due to the 
production of auto-antibodies causing inflammation and sub-
sequent tissue damage seems to be the main immunological 
event in SLE. Highly specific antibodies for SLE are those 
aimed at dsDNA and the Sm proteins (a protein complex that 
binds small nuclear RNAs). Anti-dsDNA antibodies reflect 
disease activity in SLE, especially the activity of lupus ne-
phritis [16]. Deposited ICs will induce inflammation by acti-
vating FcR-bearing immune cells such as monocytes, 
macrophages and plasmacytoid and myeloid DCs.  
 Since the genetic contribution to SLE is thought to be 
relatively large [17], it seemed likely that a genetic signature 
would be identified in SLE patients increasing their risk for 
the development of auto-antibodies and/or an increased reac-
tion toward these. A fitting association has been found be-
tween genes within the human leukocyte antigen (HLA) re-
gion on the short arm of chromosome 6 (6q21.3), especially 
in the major histocompatibility complex HLA-DRB1 and –
DQB1 loci. Polymorphisms of these determine the fitting of 
certain epitopes and thus their presentation by APCs to T 
cells. Therefore these polymorphisms determine the produc-
tion of specific auto-antibodies against nuclear antigens and 
the risk of developing SLE [18, 19]. Linked to the aberrant 
tissue deposition of ICs in SLE, preliminary evidence asso-
ciates variants of FcRIIa and IIIa with the development of 
SLE [20, 21]. These variants have been found to be less ef-
fective than their more frequent counterparts in binding ICs, 
implicating accumulation of ICs in specific tissues as an 
etiologic event in SLE. Another well-documented risk factor 
for SLE lies in the interferon regulatory factor 5 (IRF5) 
gene. The variants associated with an increased risk to SLE 
confer an augmented function of IRF5 by increasing its ex-
pression [22-24]. IRF5 is tightly involved in the signaling 
pathway utilized by TLRs activating the transcription of type 
I IFN and related proteins in APCs [25]. Since TLR7 and 
TLR8 recognize ssRNA and TLR9 recognizes unmethylated 
CpG dinucleotide containing single stranded as well as dou-
ble stranded DNA, these receptors are thought to be heavily 
involved in the pathogenesis of SLE [26]. Single nucleotide 
polymorphisms (SNPs) in STAT4, increasing its expression, 
were recently found by Sigurdsson et al. [27] to be associ-
ated with SLE. The presence of these SNPs correlated with 
the production of antibodies against dsDNA. STAT4 is acti-
vated by the ligation of the IFN receptor and is subse-
quently translocated to the nucleus, in mature DCs this in-
duces the transcription of various factors resulting in en-
hanced T cell activation [28]. In addition STAT4 transmits 
signals from the receptors of IL-12p70 and IL-23 and is cru-
cial for the development of the Th1 lineage in humans [29]. 
Interestingly, IRF5 and STAT4 are, in addition to SLE, se-
lectively associated with an increased risk for other autoim-
mune diseases with an interferon signature such as RA and 
SSc, implicating common etiologic pathways for the breach-
ing of tolerance. 
 Keeping these genetic predispositions in mind it is in-
triguing to see that the involvement of APCs and their anti-
gen uptake receptors in the pathogenesis of SLE is strongly 
supported by in vivo and in vitro human data. Raised serum 
levels of IFN have been observed in SLE patients and cor-
related with disease severity [30]. In addition peripheral 
blood cells of SLE patients demonstrated an increased tran-
scription level of type I IFN regulated genes, probably be-
cause of a continuous production of IFN [31]. A crucial 
causative role in the induction of this IFN profile might be 
the presence of RNA or DNA containing ICs. The common 
auto-antibodies in SLE like anti-dsDNA, anti-Sm proteins, 
anti-Ro proteins and anti-histone antibodies bind to either 
dsDNA or proteins complexed with RNA or DNA. These 
ICs are taken up via FcRs by APCs and by B cells via the B 
cell antigen receptor [12]. When these ICs reach the en-
dosome they subsequently trigger the intracellular TLR7, 
TLR8 or TLR9. This leads to the production of pro-
inflammatory cytokines, such as type I IFNs, the up regula-
tion of IFN regulated genes, the maturation of APCs and the 
presentation of self peptides to autoreactive T cells [32-34]. 
These autoreactive T cells in turn can help B cells in the pro-
duction of auto-antibodies. In itself, the direct activation by 
nucleic acid-containing IC of B cells additionally promotes 
auto-antibody production [35]. APCs of special interest in 
SLE are the plasmacytoid DCs. They were demonstrated to 
be the main producers of type I IFN upon stimulation with 
dsDNA or Sm containing ICs. These interferogenic ICs are 
taken up by plasmacytoid DC via FcRIIa, are translocated 
to the endosome and then stimulate the relevant TLR result-
ing in a massive release of IFN [36, 37]. However, since 
monocytes, macrophages and myeloid DCs express high 
levels of FcRs and respond vigorously to stimulation with 
TLR7/8 ligands, nucleic acid containing ICs might also acti-
vate these cells to produce pro-inflammatory cytokines. This 
was previously demonstrated by Boulé et al. using murine 
bone-marrow DCs which produced TNF and BAFF upon 
the stimulation with chromatin IC [32]. Myeloid DCs, upon 
the activation with TLR7/8 ligands are able to secrete high 
levels of IL-12p70 and induce the proliferation of Th1 cells, 
especially in combination with IFN, IFN or TLR4 ligands 
[10, 38, 39]. IL-12p70 is the major cytokine in inducing Th1 
responses and thus the production of IFN. Blood IL-12p70 
and IFN are elevated in SLE patients and IL-12p70 levels 
correlate with the SLE disease activity index (SLEDAI) in 
SLE patients with renal involvement [40, 41]. Correspond-
ingly, the ratio of IFN/IL-4-producing CD4+ T cells corre-
lates with the SLEDAI and was significantly higher among 
patients with lupus nephritis [42]. In addition, IFN was 
demonstrated to contribute heavily to nephritis in murine 
lupus [43]. Nucleic acid-containing ICs may thus start a vi-
cious circle by inducing IFN from plasmacytoid DCs. In 
this conceptual framework the released IFN then primes 
monocytes and myeloid DCs for TLR7/8 activation by nu-
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cleic acid containing ICs resulting in a synergistic release of 
IL-12p70. The high levels of IL-12p70 favor the presence of 
Th1 cells and thus the release of IFN. IFN in itself primes 
myeloid lineage cells for the internalization of ICs, the re-
lease of IL-12p70 and the presentation of self peptides to 
autoreactive T cells enabling them to help B cells produce 
antibodies against nucleic acids or proteins bound to these. 
An observation supportive of this hypothesis was that in 
SLE, monocyte-derived and myeloid DCs are in a pre-
activated state promoting DC maturation, pro-inflammatory 
cytokine release and T cell proliferation [44]. Interestingly, 
as described above, genes involved in the production of type 
I IFN and IL-12p70 (IRF5) and its signal transduction in 
APCs and T cells (STAT4) are heavily implicated in the sus-
ceptibility for SLE and might thus contribute to this self-
sustaining menacing loop [22-24, 27]. An additional mecha-
nism which might support this vicious circle is the myeloid 
DC-inducing capacity of SLE serum, mediated through the 
effect of IFN on monocytes [45]. The promotion of the 
differentiation of B cells into plasmablasts and antibody-
secreting plasma cells by pDCs activated with SLE ICs 
seems to be another contributing factor [46]. Of interest, 
crossing of mice lacking the inhibitory FcRIIb to the Y-
linked autoimmune accelerator (Yaa) locus, which harbors a 
duplication in the TLR7 gene, markedly enhanced autoim-
munity [47], stressing the importance of FcR and TLR co-
operation in the maintenance of tolerance and the induction 
of autoimmunity.  
 The involvement in the pathogenesis of SLE of the type I 
IFN system consisting of nucleic acid containing ICs and 
TLRs has been subject of intense investigation during the 
past years in animal models of SLE. A large body of suppor-
tive data has emerged from these studies. The importance of 
signaling through the IFN receptor was apparent from ex-
perimental murine lupus models in which IFN receptor 
knock-out mice had a markedly reduced SLE disease [48]. 
The essential role played by TLR7 in the pathogenesis of 
SLE was emphasized by studies demonstrating that mice 
lacking this receptor do not produce anti-Sm antibodies and 
have an ameliorated clinical disease [49]. The blockade of 
TLR7 with synthetic oligodeoxynucleotides in MRL(lpr/lpr) 
mice also reduced the levels of anti-Sm and anti-dsDNA 
antibodies and ameliorated lupus nephritis [50, 51]. In addi-
tion, over expression of TLR7 accelerated systemic autoim-
munity in murine lupus [52]. The role for TLR9 was less 
clear, whereas triggering of TLR9 with CpG oligonucleo-
tides in MRL(lpr/lpr) mice induced nephritis [53]. Absence 
of this receptor accelerated clinical disease in MRL(lpr/lpr) 
mice although it did prevent the occurrence of anti-dsDNA 
antibodies [54].  
 These emerging data suggestive of a causal relationship 
between auto-antibodies, an over-activated type I IFN sys-
tem and SLE indicate that these could be therapeutic targets. 
Supportive are data from two effective therapeutic agents in 
SLE, hydroxychloroquine and glucocorticoids. These drugs 
prevent activation of the intracellular TLRs, inhibit IFN 
production by pDCs and suppress the IFN signature [55, 56]. 
Interestingly, preliminary results from a phase I clinical trial 
with a neutralizing antibody against IFN were very encour-
aging with a dose-dependent inhibition of type I IFN-
inducible genes as well as a prominent reduction in clinical 
disease activity [57]. In another clinical trial (phase III) an 
agent (Abetimus sodium) selectively aimed at removing anti-
dsDNA antibodies from the blood was used. Although not all 
clinical parameters improved notably a significant reduction 
in SLEDAI and proteinuria was observed corresponding to 
the reduction of circulating anti-dsDNA antibodies, under-
scoring the pathological role of these antibodies. A possible 
explanation for the limited clinical effect of this agent might 
be that the remaining RNA-containing IC induced sufficient 
amounts of IFN to maintain the chronic inflammatory 
process [58].  
RHEUMATOID ARTHRITIS 
 RA is a systemic autoimmune disease characterized by 
chronic synovial inflammation and subsequent damage to 
cartilage and bone, leading to severe disabilities. Most RA 
patients have auto-antibodies against the Fc portion of IgG 
molecules (Rheumatoid Factor) and citrullinated proteins. 
The most frequent proteins against which anti-citrullinated 
protein/peptide antibodies (ACPAs) are produced are fi-
brinogen and -enolase, which are abundantly present in the 
RA synovium [59, 60]. The presence of these auto-
antibodies is associated with a more aggressive disease 
course suggesting a pathogenic role in RA [61]. There is a 
large disease heterogeneity highlighted by different re-
sponses to medication such as the anti-TNF antibodies.  
 During RA there is a massive influx of immune cells into 
the synovial cavity, including monocytes, macrophages, 
dendritic cells (DCs), T cells and B cells. Genetic evidence 
points towards an important role for APCs and their antigen-
uptake receptors in the pathogenesis of RA. The strongest 
association with RA susceptibility and disease severity has 
been found in the HLA-DRB1 gene [62-64]. Multiple RA 
risk alleles within the HLA-DRB1 gene share a conserved 
amino acid sequence and are therefore known as ‘shared 
epitope’ alleles [65]. These polymorphisms are present in the 
epitope binding region of the major histocompatibility com-
plex II (MHC) and thereby probably influence antigen pres-
entation by APCs and autoantibody production [66]. Recent 
data shows that shared epitope alleles of the MHC-II are 
specifically associated with anti-CCP positive RA [67, 68]. 
More recently also non-HLA genes have been linked to RA 
susceptibility and disease severity. Variants of the activating 
Fc gamma receptors FcRIIIa and FcRIIIb have been asso-
ciated with RA susceptibility in Europeans, but not in Asians 
[69, 70]. The FcRIIIa variant is less effective in IC binding, 
implicating impaired clearance of ICs might play a role in 
the pathogenesis of RA, similar to SLE[71]. A functional 
variant of the inhibitory FcRIIb is associated with disease 
severity rather than susceptibility [72]. APCs from patients 
with this variant fail to develop an inhibitory phenotype 
upon IC binding, thereby stimulating pro-inflammatory im-
mune responses and subsequent joint damage. Similar to 
SLE, the IRF5 and STAT4 genes are also important risk fac-
tors for RA [73, 74]. These genes are involved in the type I 
IFN system in APC, activated as a part of the TLR signaling 
pathway. These common denominators suggest that, like in 
SLE, the type I IFN system might play a role in the breach-
ing of tolerance in RA. TLR involvement is further sug-
gested by a functional variant of the TLR4 gene that reduces 
the response to LPS and thereby decreases the susceptibility 
to RA [75], although not significant in another study [76].  
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 The involvement of APCs and their antigen uptake recep-
tors in the pathogenesis of RA is not restricted to genetic 
predisposition, but is further supported by in vitro and in 
vivo data. In RA synovial tissue, the expression of TLR2, 3, 
4 and 7 is increased compared to healthy controls or os-
teoarthritis patients [39, 77-79]. RA synovial fibroblasts pro-
duce increased amounts of chemokines upon stimulation 
with TLR2 ligands [80]. Similarly, monocyte-derived DCs 
from RA patients also show an increased responsiveness to 
TLR2 and TLR4 ligands, resulting in increased production 
of pro-inflammatory cytokines [39]. Tissue damage and cell 
stress during synovial inflammation can lead to the produc-
tion of heat shock proteins (HSPs), altered fibronectin or low 
molecular weight hyaluronan fragments and RNA release 
from necrotic cells. These are endogenous TLR ligands that 
in turn can activate synovial fibroblasts and APCs via TLR2, 
TLR4 and TLR3, stimulating chronic inflammation [9, 78, 
81-83]. Necrotic cells in the RA synovium may also release 
citrullinated proteins and activated citrullinating peptidy-
larginine deaminases (PADs). These enzymes can citrullinate 
for example fibrin(ogen) present in large amounts in the RA 
synovium. When these proteins are not degraded properly, 
they can be taken up by APCs and presented to T cells which 
in turn can trigger autoreactive B cells to produce ACPAs. 
Locally produced ICs can induce TNF production by 
monocytes and macrophages via FcRIIa and thereby aggra-
vate local inflammation and promote chronicity [84-86]. 
Recently, TLR8 has also been shown to be important for 
TNF production in RA synovial tissue. Inhibition of TLR8 
was able to inhibit spontaneous TNF production by RA 
synovial membrane cultures [87]. Stimulation of TLR8 by an 
unknown ssRNA containing component present in the RA 
synovium appears to lead to pro-inflammatory cytokine pro-
duction, including type I IFNs, and might support APC 
maturation and subsequent presentation of (self) peptides to 
(autoreactive) T cells. These findings, together with genetic 
data concerning IRF5 and STAT4, are indicative of a role for 
type I IFNs in RA. Supportive of this are the high levels of 
IFN found in RA synovial tissue and the selective up regu-
lation of type I IFN-response genes in peripheral blood cells 
from a subgroup of RA patients [10, 88]. In addition, it was 
recently reported that SLE features are common in RA pa-
tients given sufficient observation time and that these were 
associated with increased mortality [89]. Refuting a role for 
type I IFN in the pathogenesis of RA are the clinical advan-
tages that have been made in RA using anti-TNF antibod-
ies. The production of type I IFN by plasmacytoid DCs is 
enhanced by blocking TNF [90]. A known side effect of 
anti-TNF therapy is the occurrence of antinuclear antibod-
ies and anti-dsDNA antibodies which might even culminate 
in full-blown glomerulonephritis [91]. However, even anti-
TNF therapy is successful in only a subpopulation of RA 
patients underscoring the existence of diverse pathways lead-
ing to autoimmunity. As in SLE, it might be possible that the 
endocytosis pathway by which the ssRNA is delivered to the 
intracellular TLR8 is mediated via antibodies and FcRs. 
Immune complexes in joints might thus provide a direct link 
to cytokine dependent inflammation in RA, via APCs. Co-
herently, APCs from RA patients have been shown to pro-
duce more TNF upon IC triggering than healthy control 
APCs, which can be explained by increased expression of 
FcRII and FcRIII on these cells [92, 93]. High expression 
of the inhibitory FcRIIb could play an important role in 
controlling inflammation by inhibition of activating FcRs 
and TLR4 induced cytokine production in macrophages and 
DCs [5, 94]. Highly increased FcRIIb expression on mono-
cyte-derived DCs from RA patients that have sustained low 
disease activity without the need of medication underscores 
the importance of this feedback mechanism in RA [5].  
 FcR knockout studies confirm the important role of 
FcRs in arthritis. Several studies have shown that the pres-
ence of activating FcRs was associated with increased 
chondrocyte death and cartilage erosion and that FcRIII 
knockout mice are protected from IC-induced arthritis[95-
99]. Inhibition of spleen tyrosine kinase (Syk), a key media-
tor of activating FcRs and B cell receptor signaling, also 
shows suppression of inflammation and bone erosion, high-
lighting a possible role of activating FcRs in arthritis mod-
els [100]. On the other hand, deletion of the inhibitory 
FcRII (mice lack FcRIIa) induced arthritis even in non-
susceptible mice [101]. FcRIIb not only inhibits activating 
FcRs, but is also important for effective clearance of ICs 
[102]. Furthermore, FcRIIa transgenic mice are hyper-
responsive to pathogenic antibodies and blocking of this re-
ceptor in these mice inhibited development and stopped pro-
gression of collagen-induced arthritis [103]. These data 
clearly show the importance of activating FcRs on APCs in 
the initiation and progression of arthritis, which is in line 
with the in vitro data showing involvement of activating 
FcRs in pro-inflammatory cytokine production and inhibi-
tion of this by FcRIIb. Experimental arthritis models have 
also contributed to our understanding of the role of TLRs in 
RA. Classical animal models such as streptococcal cell wall 
(SCW) arthritis and autoimmune arthritis in IL-1 receptor 
antagonist-knockout (IL-1ra-/-) mice are dependent on acti-
vation of the innate immune system via TLRs. The acute 
phase of SCW induced arthritis is dependent of TLR2, while 
the TLR dependency shifts towards TLR4 in the chronic 
phase. This occurs simultaneously with the transition from a 
macrophage driven arthritis to a T cell dependent process 
[102]. Arthritis development in IL-1ra -/- mice can also be 
regulated by TLRs, since TLR2 knockout mice develop a 
more severe arthritis while TLR4 knockouts were protected 
against severe arthritis. Selective blocking of TLR4 was also 
able to diminish severity of experimental arthritis [104]. A 
role for TLRs is further supported by studies that show a 
self-limited form of arthritis in mice after synovial injection 
of TLR ligands, such as CpG DNA, dsRNA or staphylococ-
cal peptidoglycans [105-107].  
 APCs and their cytokines have been proven to be an ef-
fective therapeutic target in the treatment of RA. Therapies 
often used now are biologicals directed against effector 
molecules like TNF (adalimumab, etanercept, and inflixi-
mab), IL-6 (tocilizumab) or IL-1 (anakinra), molecules pro-
duced by APCs as a response to TLR stimulation or antigen 
uptake via FcRs. The development of TNF antagonists had 
a great impact on treatment of RA patients, although still 
about 30% of the patients fails to respond to TNF antagonists 
or has to discontinue treatment due to adverse effects [108, 
109]. Another effective therapy directed against APCs is 
abatacept, which binds to CD80/CD86 on the APC and pre-
vents T cell activation [110-112]. Medication more specifi-
cally directed against antigen-uptake receptors or TLRs are 
already used for several years and more are under investiga-
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tion. The combination of methotrexate and hydroxychloro-
quine, which prevents intracellular TLR activation, shows 
increased effectiveness compared to methotrexate alone 
[113-116], although this might partially be due to an in-
creased bioavailability of methotrexate [117]. The effective-
ness of direct targeting of TLRs in RA is also supported by a 
phase II clinical trial with chaperonin 10, that inhibits TLR2 
and TLR4 signaling [118]. No placebo was used in this trial, 
so confirmation of its potential is necessary, but it suggests 
quick and sustained improvement of symptoms during the 12 
weeks follow up. However, there are some considerations 
concerning possible adverse effects during long-term use, 
since chaperonin 10 has also been described in carcinogene-
sis [119, 120]. Long term studies have to show if chaperonin 
10 could be used in the treatment of RA or not. Since Syk is 
involved in FcR and B cell receptor signaling inhibition of 
this tyrosine kinase could reduce IC mediated inflammation 
and B cell responses, suggesting great potential in RA treat-
ment. A 12 week, randomized clinical trial has already dem-
onstrated superior clinical efficacy of an oral Syk kinase 
inhibitor, R788 compared to placebo [121].  
SYSTEMIC SCLEROSIS 
 Systemic sclerosis (SSc) is a heterogenous autoimmune 
disease characterized by fibrosis of the skin and the internal 
organs, leading to sever debilitation and eventually death. 
The prevalence and incidence of SSc varies greatly depend-
ing on geographical location and ethnicity but it is clear that 
women are affected more often than men with a ratio ranging 
from 4:1 to 14:1 [122]. Over the past year clinical outcomes 
have improved, presumable due to better management of 
complications, but still SSc is considered incurable. As most 
autoimmune diseases SSc is a heterogeneous disease. Clini-
cally it can be subdivided in two entities on the extent of skin 
involvement; limited SSc (limSSc) defined as fibrosis distal 
to the elbow and knee joint and the face, and the diffuse 
form with more proximal fibrosis [2]. The diffuse cutaneous 
form (dSSc) is the most fatal connective tissue disease 
known with 55% survival at 10 years [123]. The etiology is 
still unknown but prominent features are vascular injury and 
chronic inflammation resulting in fibrosis. Evidence for an 
autoimmune process causing this inflammation is growing, 
for example exposed by the presence of auto-antibodies in 
90% of SSc patients.  
 As for the autoimmune diseases described above, the 
genetic make-up seems to determine the chance of develop-
ing SSc in response to an external trigger. This is demon-
strated by the fact that a positive family history is the strong-
est risk factor thus far identified in SSc [124] although con-
cordance is still weak [125]. Furthermore SSc is now associ-
ated with a sizable number of SNPs in an increasing number 
of genes [126]. Like in other autoimmune diseases the HLA 
region is a region of interest in SSc. However there is a lack 
of consensus concerning the contribution of these alleles in 
SSc. A consistent finding in this discussion seems to be the 
association between anti-topoisomerase I (anti-topo I) and 
the HLA-DR region [127-129] suggesting a contribution of 
auto-antibodies in the pathogenesis. As reported in SLE and 
RA there is an association between the possession of the 
SNP rs2004640 in IRF5 and susceptibility to SSc [130] (and 
unpublished observations). This SNP results in the produc-
tion of a different isotype from IRF5 leading to a different 
transcription of target pro-inflammatory cytokines which are 
known to increase the risk for developing SLE [131]. Next to 
that, recent data show an association between STAT-4 SNPs 
and disease phenotype favoring limited SSc [132]. Both as-
sociations suggest a role for TLR signaling and the IFN 
pathway in SSc as shown for SLE and RA but further re-
search to unravel consequences of these SNPs is needed. 
 Anti-topo I and anti-centromere antibodies (ACA) are 
generally known to characterize specific clinical subsets with 
Anti-topo I being more prevalent in dSSc and ACA in 
limSSc [133]. In line with findings in SLE, data on an IFN 
type I signature are growing [134-136] and a recent report 
from Kim et al. [137] showed interferogenic activity by anti-
topo I ICs. Although a role for type I IFNs in SSc is counter-
intuitive knowing that these IFN are potent inhibitors of col-
lagen production in fibroblasts [138], a report describing the 
rapid onset of SSc symptoms in patients treated with intense 
IFN therapy suggests a clear pathologic contribution of 
IFNs to the development of SSc [139]. In view of this, plas-
macytoid DC (pDCs) are interesting due to their potential of 
producing high levels of type I IFNs. Kim et al. showed that 
interfering with FcRIIa or RNAse treatment suppresses the 
IFN production upon stimulation with anti-topo I antibodies 
[137]. This implicates that like anti-Sm antibodies in SLE, 
anti-topo I antibodies are taken up by pDCs via FcRIIa and 
subsequently activate TLR7 inducing the production of 
IFN. In contrast, ACA did not induce the production of 
IFN. Since anti-topo I and ACA are predominantly found 
in patients with dSSc and limSSc, respectively, a role for 
IFN in disease severity seems likely. Type I IFNs have a 
known anti-angiogenic and pro-apoptotic effect on endothe-
lial cells implicating a role in SSc vascular distress. High-
lighting this, endothelial cells in SSc express a type I inter-
feron signature [134, 140]. In the last years more auto-
antibodies were identified and their contribution to the dis-
ease was investigated. For example, antibodies directed 
against FcR and especially FcRIII were described. This 
was suggested to reduce the ability of FcR to phagocytose 
immune complexes [141, 142]. Other antibodies target fi-
broblasts (anti-fibroblast antibodies (AFA) and anti-platelet-
derived growth factor (PDGF) receptor) [143]. Stimulation 
of fibroblasts through TLR4, possibly by these auto-
antibodies, up regulates a chemokine transcription program, 
skewed towards pro-fibrotic activities, for example increased 
CCL2 production. The importance of this is illustrated by the 
fact that CCL2 is abundantly present in SSc [144-147] and 
most interestingly CCR2-/- mice are resistant to the devel-
opment of lung fibrosis induced by bleomycin [148]. More 
intriguing recent literature suggests that signaling through 
TLRs plays a role in maintaining the heightened state of ac-
tivation of the myofibroblast as seen during fibrosis [149]. 
These findings together with the presence of endogenous 
TLR4 ligands in the circulation of SSc patients [39] suggests 
that signaling through these receptors could induce chronic 
systemic fibrosis in the susceptible host.  
 An initial pathological finding in SSc dermal tissue is 
rarefaction of capillaries and the infiltration of mononuclear 
cells [150, 151]. These cellular infiltrates consist mainly of 
myeloid APCs and CD4
+
 T-cells. The role of the immune 
system in the development of SSc has been investigated in 
several animal models. In UCD 200 chicken, for example, 
dermal and visceral fibrosis is also preceded by mononuclear 
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infiltration demonstrating the role of inflammatory cells in 
initiating fibrosis [152, 153]. Thight Skin-2 mice (Tsk-2), 
another SSc animal model, also show this early mononuclear 
cell infiltration together with autoantibody production re-
sembling human SSc [154, 155]. Bleomycin is a glycopep-
tide antibiotic used as a chemotherapeutic agent, well-known 
side effects are lung fibrosis and Raynaud’s phenomenon. 
Repeated subcutaneous injections of bleomycin in shaved 
back skin induced dermal fibrosis closely resembling SSc 
[156]. In the murine bleomycin model immune cells are acti-
vated by hyaluronan via TLR4 (and directly by bleomycin 
via TLR2 [157]) and auto-antibody production is induced 
resulting in a scleroderma like phenotype [158].  
 The increasing amount of evidence illustrating the role of 
APCs in the pathogenesis of SSc can offer new insights in 
the pathogenesis of this disease and thus offer new therapeu-
tic targets. As an example, the data above suggest that in SSc 
APCs infiltrate the diseased tissue, are activated through 
their TLRs and activate a cascade resulting in fibrosis. Inter-
fering in this cascade is just one interesting example. A 
therapeutic target might be BDCA-2, a C-type lectin receptor 
exclusively present on pDCs. Ligation of BDCA-2 inhibits 
the production of type I IFN of pDCs upon anti-topo I stimu-
lation by interfering with the uptake via FcRIIa and signal-
ing through TLRs [137]. Activation of pDC via BDCA-2 
might thus reduce the pro-inflammatory and anti-angiogenic 
effect of these ICs. Current therapeutic options in SSc are 
very limited. Administrations of cyclophosphamide or 
autologous stem cell transplantation currently are the only 
therapies with some effect [159], although the results of the 
bigger trials are still to be expected [160]. As these therapies 
attack the whole cellular balance it is impossible to speculate 
on a specific contribution.  
CONCLUSION  
 A large body of evidence points towards a seminal role 
for APCs and their uptake receptors in the development of 
autoimmune diseases. Striking similarities in many genetic 
and pathophysiological features in autoimmune diseases like 
SLE, RA and SSc were described despite their apparent dis-
similar characteristics (Table 1). A fitting explanation for 
this issue appears to be the HLA-DRB1 gene which is asso-
ciated with all these diseases. Since there is almost no over-
Table 1. Highlighting Some Current Data Available on the Role Played by APCs, their FcRs and TLRs and their Products 


















In vivo  Increased transcription of type I IFN 
regulated genes in peripheral blood cells. 
[31] 
Increased levels of IFN correlated with 
disease severity. [30] 
Increased IL-12p70 levels correlating 
with SLEDAI. [40,41] 
Increased TLR2, 3, 4, 7 expression and pres-
ence of endogenous TLR4 ligands in RA 
synovial tissue. [39, 77-79] 
Increased transcription of type I IFN regu-
lated genes in blood. [88] 
IFN expression in RA synovial tissue. [10] 
Increased transcription of 
certain type I IFN regulated 
genes in peripheral blood 
cells. [135] 
Endogenous TLR4ligands in 
serum. [39] 
Myeloid APCs in diseased 
skin. [150-151] 
In vitro ICs from SLE patients induce the release 
of IFN by plasmacytoid DCs via TLR7 
and TLR9. [36,37] 
Monocyte-derived and myeloid DCs 
from SLE patients demonstrate increased 
maturation and cytokine release. [44] 
RA synovial tissue fibroblasts and mono-
cyte-derived DCs display an increased re-
sponse to TLR stimulation. [39,80] 
ICs in synovial fluid induce TNF release 
from monocytes. [92,93] 
TLR8 inhibition prevents “spontaneous” 
cytokine release by synovial tissue. [87] 
Interferogenic activity of anti-
topoisomerase ICs on plas-




TLR7-/- mice do not develop anti-Sm 
antibodies and have a less severe disease. 
[49] 
TLR7 over expression results in in-
creased autoimmunity. [52] 
IFNR-/- mice develop less severe lu-
pus-like disease. [48] 
FcRIII-/- mice are protected from IC-
induced arthritis. [97, 99] 
FcRII-/- mice are more susceptible and have 
a worse arthritis. [101] 
Knocking out of TLR4 or the blockade of 
TLR4 reduces arthritis in multiple models. 
[102, 104] 
Syk inhibitors suppress inflammation and 
bone erosion. [100] 
UCD 200 chicken, Tsk2 mice 
and bleomycin induced SSc 
show mononuclear cell infil-
trates and autoantibody pro-
duction. [152-156] 
Signaling through TLR4 in 







by APCs and 
their recep-
tors) 
HCQ and glucocorticoids [55,56] 
Anti-IFN antibodies [57] 
Abetimus sodium [58] 
HCQ and glucocorticoids [113-116] 
Abatacept [110-112] 
Chaperonin 10 [118] 
Syk inhibitor, R788 [121] 
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lap between the polymorphisms within this gene [161] and 
most are located within the epitope binding region, the 
MHC-II variant probably determines the antigen against 
which auto-antibodies are produced and thus which clinical 
phenotype occurs. FcRs and TLRs expressed by APCs are 
crucial receptors of the immune system forming a bridge 
between innate and adaptive immunity. In autoimmunity 
these receptors appear to direct immune responses towards 
self by enabling the uptake of immune complexes containing 
(nucleic) self-antigens. These ICs induce the release of pro-
inflammatory cytokines, such as type I IFNs, by APCs and 
forces them to mature. These mature APCs then induce the 
differentiation and proliferation of auto-reactive T cells, a 
crucial event in the pathogenesis of autoimmunity. Next to 
this the type I IFN system is unequivocally entangled in the 
pathogenesis of SLE and appears to have contributing roles 
to both RA and SSc. These findings underscore the potential 
of treatments aimed at APCs. Accordingly, in the past, pre-
sent and future the most promising targets in the enduring 
battle against autoimmunity appear to be these cells them-
selves, their receptors and their products.  
REFERENCES 
[1] Hochberg MC. Updating the American College of Rheumatology 
revised criteria for the classification of systemic lupus erythemato-
sus. Arthritis Rheum 1997; 40: 1725. 
[2] LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic 
sclerosis); classification, subsets and pathogenesis. J Rheumatol 
1988; 15: 202-5. 
[3] Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheuma-
tism Association 1987 revised criteria for the classification of 
rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. 
[4] Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young 
JW. Activating and inhibitory IgG Fc receptors on human DCs 
mediate opposing functions. J Clin Invest 2005; 115: 2914-23. 
[5] Wenink MH, Santegoets KC, Roelofs MF, et al. The inhibitory 
Fc(gamma)IIb receptor dampens TLR4-mediated immune re-
sponses and is selectively up-regulated on dendritic cells from 
rheumatoid arthritis patients with quiescent disease. J Immunol 
2009; 183: 4509-20. 
[6] Ronnblom L, Eloranta ML, Alm GV. The type I interferon system 
in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 408-
20. 
[7] Martin DA, Elkon KB. Autoantibodies make a U-turn; the toll 
hypothesis for autoantibody specificity. J Exp Med 2005; 202: 
1465-9. 
[8] Deane JA, Bolland S. Nucleic acid-sensing TLRs as modifiers of 
autoimmunity. J Immunol 2006; 177: 6573-8. 
[9] Roelofs MF, Boelens WC, Joosten LA, et al. Identification of small 
heat shock protein B8 (HSP22) as a novel TLR4 ligand and poten-
tial involvement in the pathogenesis of rheumatoid arthritis. J  
Immunol 2006; 176: 7021-7. 
[10] Roelofs MF, Wenink MH, Brentano F, et al. Type I interferons 
might form the link between Toll-like receptor (TLR) 3/7 and 
TLR4 mediated synovial inflammation in rheumatoid arthritis 
(RA). Ann Rheum Dis 2009; 68(9): 1486-93. 
[11] Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced 
autoimmune heart failure requires cooperation between adaptive 
and innate immunity. Nat Med 2003; 9: 1484-90. 
[12] Marshak-Rothstein A. Toll-like receptors in systemic autoimmune 
disease. Nat Rev Immunol 2006; 6: 823-35. 
[13] Ronnblom L, Pascual V. The innate immune system in SLE; type I 
interferons and dendritic cells. Lupus 2008; 17: 394-9. 
[14] Lafyatis R, Marshak-Rothstein A. Toll-like receptors and innate 
immune responses in systemic lupus erythematosus. Arthritis Res 
Ther 2007; 9: 222. 
[15] D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythe-
matosus. Lancet 2007; 369: 587-96. 
[16] Neogi T, Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA anti-
body testing by Farr and ELISA techniques is not equivalent. J 
Rheumatol 2006; 33: 1785-8. 
[17] Criswell LA. The genetic contribution to systemic lupus erythema-
tosus. Bull NYU Hosp Jt Dis 2008; 66: 176-83. 
[18] Graham RR, Ortmann W, Rodine P, et al. Specific combinations of 
HLA-DR2 and DR3 class II haplotypes contribute graded risk for 
disease susceptibility and autoantibodies in human SLE. Eur J Hum 
Genet 2007; 15: 823-30. 
[19] Fernando MM, Stevens CR, Sabeti PC, et al. Identification of two 
independent risk factors for lupus within the MHC in United King-
dom families. PLoS Genet 2007; 3: e192. 
[20] Karassa FB, Trikalinos TA, Ioannidis JP. Role of the Fcgamma 
receptor IIa polymorphism in susceptibility to systemic lupus 
erythematosus and lupus nephritis; a meta-analysis. Arthritis 
Rheum 2002; 46: 1563-71. 
[21] Karassa FB, Trikalinos TA, Ioannidis JP. The Fc gamma RIIIA-
F158 allele is a risk factor for the development of lupus nephritis; a 
meta-analysis. Kidney Int 2003; 63: 1475-82. 
[22] Ferreiro-Neira I, Calaza M, Alonso-Perez E, et al. Opposed inde-
pendent effects and epistasis in the complex association of IRF5 to 
SLE. Genes Immun 2007; 8: 429-38. 
[23] Castro J, Balada E, Ordi-Ros J, Vilardell-Tarres M. The complex 
immunogenetic basis of systemic lupus erythematosus. Autoimmun 
Rev 2008; 7: 345-51. 
[24] Kozyrev SV, Lewen S, Reddy PM, et al. Structural inser-
tion/deletion variation in IRF5 is associated with a risk haplotype 
and defines the precise IRF5 isoforms expressed in systemic lupus 
erythematosus. Arthritis Rheum 2007; 56: 1234-41. 
[25] Graham RR, Kozyrev SV, Baechler EC, et al. A common haplo-
type of interferon regulatory factor 5 (IRF5) regulates splicing and 
expression and is associated with increased risk of systemic lupus 
erythematosus. Nat Genet 2006; 38: 550-5. 
[26] Yasuda K, Richez C, Uccellini MB, et al. Requirement for DNA 
CpG content in TLR9-dependent dendritic cell activation induced 
by DNA-containing immune complexes. J Immunol 2009; 183: 
3109-17. 
[27] Sigurdsson S, Nordmark G, Garnier S, et al. A risk haplotype of 
STAT4 for systemic lupus erythematosus is over-expressed, corre-
lates with anti-dsDNA and shows additive effects with two risk al-
leles of IRF5. Hum Mol Genet 2008; 17: 2868-76. 
[28] Longman RS, Braun D, Pellegrini S, Rice CM, Darnell RB, Albert 
ML. Dendritic-cell maturation alters intracellular signaling net-
works, enabling differential effects of IFN-alpha/beta on antigen 
cross-presentation. Blood 2007; 109: 1113-22. 
[29] Chang HC, Han L, Goswami R, et al. Impaired development of 
human Th1 cells in patients with deficient expression of STAT4. 
Blood 2009; 113(23): 5887-90. 
[30] Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I 
interferon system in systemic lupus erythematosus correlates with 
disease activity but not with antiretroviral antibodies. Lupus 2000; 
9: 664-71. 
[31] Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible 
gene expression signature in peripheral blood cells of patients with 
severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-5. 
[32] Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein 
A, Rifkin IR. Toll-like receptor 9-dependent and -independent den-
dritic cell activation by chromatin-immunoglobulin G complexes. J 
Exp Med 2004; 199: 1631-40. 
[33] Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L.  
Patients with systemic lupus erythematosus (SLE) have a circulat-
ing inducer of interferon-alpha (IFN-alpha) production acting on 
leucocytes resembling immature dendritic cells. Clin Exp Immunol 
1999; 115: 196-202. 
[34] Bave U, Alm GV, Ronnblom L. The combination of apoptotic 
U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 
2000; 165: 3519-26. 
[35] Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlom-
chik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate 
B cells by dual engagement of IgM and Toll-like receptors. Nature 
2002; 416: 603-7. 
[36] Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster 
AD. Human lupus autoantibody-DNA complexes activate DCs 
through cooperation of CD32 and TLR9. J Clin Invest 2005; 115: 
407-17. 
[37] Savarese E, Chae OW, Trowitzsch S, et al. U1 small nuclear ribo-
nucleoprotein immune complexes induce type I interferon in plas-
macytoid dendritic cells through TLR7. Blood 2006; 107: 3229-34. 
[38] Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. 
Selected Toll-like receptor agonist combinations synergistically 
trigger a T helper type 1-polarizing program in dendritic cells. Nat 
Immunol 2005; 6: 769-76. 
[39] Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, et al. The expres-
sion of toll-like receptors 3 and 7 in rheumatoid arthritis synovium 
is increased and costimulation of toll-like receptors 3, 4, and 7/8 re-
44    The Open Arthritis Journal, 2010, Volume 3 Santegoets et al. 
sults in synergistic cytokine production by dendritic cells. Arthritis 
Rheum 2005; 52: 2313-22. 
[40] Tokano Y, Morimoto S, Kaneko H, et al. Levels of IL-12 in the 
sera of patients with systemic lupus erythematosus (SLE)--relation 
to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999; 116: 
169-73. 
[41] Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyper-
production of IL-23 and IL-17 in patients with systemic lupus 
erythematosus; implications for Th17-mediated inflammation in 
auto-immunity. Clin Immunol 2008; 127: 385-93. 
[42] Sugimoto K, Morimoto S, Kaneko H, et al. Decreased IL-4 produc-
ing CD4+ T cells in patients with active systemic lupus erythema-
tosus-relation to IL-12R expression. Autoimmunity 2002; 35: 381-
7. 
[43] Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta 
G. Experimental therapy of systemic lupus erythematosus; the 
treatment of NZB/W mice with mouse soluble interferon-gamma 
receptor inhibits the onset of glomerulonephritis. Eur J Immunol 
1995; 25: 6-12. 
[44] Ding D, Mehta H, McCune WJ, Kaplan MJ. Aberrant phenotype 
and function of myeloid dendritic cells in systemic lupus erythema-
tosus. J Immunol 2006; 177: 5878-89. 
[45] Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction 
of dendritic cell differentiation by IFN-alpha in systemic lupus 
erythematosus. Science 2001; 294: 1540-3. 
[46] Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, 
Banchereau J. Plasmacytoid dendritic cells induce plasma cell dif-
ferentiation through type I interferon and interleukin 6. Immunity 
2003; 19: 225-34. 
[47] Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T,  
Satterthwaite AB, Bolland S. Autoreactive B cell responses to  
RNA-related antigens due to TLR7 gene duplication. Science 2006;  
312: 1669-72. 
[48] Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I 
interferon receptor deficiency reduces lupus-like disease in NZB 
mice. J Exp Med 2003; 197: 777-88. 
[49] Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, 
Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody 
specificity and have opposing inflammatory and regulatory roles in 
a murine model of lupus. Immunity 2006; 25: 417-28. 
[50] Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, 
Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 
plus TLR-9 attenuates glomerulonephritis and lung injury in ex-
perimental lupus. J Am Soc Nephrol 2007; 18: 1721-31. 
[51] Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treat-
ment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 
leads to reduction of autoantibody production and amelioration of 
disease symptoms. Eur J Immunol 2007; 37: 3582-6. 
[52] Subramanian S, Tus K, Li QZ, et al. A Tlr7 translocation acceler-
ates systemic autoimmunity in murine lupus. Proc Natl Acad Sci 
USA 2006; 103: 9970-5. 
[53] Pawar RD, Patole PS, Ellwart A, et al. Ligands to nucleic acid-
specific toll-like receptors and the onset of lupus nephritis. J Am 
Soc Nephrol 2006; 17: 3365-73. 
[54] Ma Z, Chen F, Madaio MP, Cohen PL, Eisenberg RA. Modulation 
of autoimmunity by TLR9 in the chronic graft-vs-host model of 
systemic lupus erythematosus. J Immunol 2006; 177: 7444-50. 
[55] Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis 
signatures in systemic lupus erythematosus blood. J Exp Med 2003; 
197: 711-23. 
[56] Lebon P. Inhibition of herpes simplex virus type 1-induced inter-
feron synthesis by monoclonal antibodies against viral glycoprotein 
D and by lysosomotropic drugs. J Gen Virol 1985; 66(Pt12): 2781-
6. 
[57] Wallace DJ. MEDI-545, an anti-interferon alpha monoclonal anti-
body, shows evidence of clinical activity in systemic lupus erythe-
matosus. ACR/ARHP Scientific Meeting: Boston 2007. 
[58] Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. 
Abetimus sodium for renal flare in systemic lupus erythematosus; 
results of a randomized, controlled phase III trial. Arthritis Rheum 
2008; 58: 2470-80. 
[59] Zhao X, Okeke NL, Sharpe O, et al. Circulating immune com-
plexes contain citrullinated fibrinogen in rheumatoid arthritis.  
Arthritis Res Ther 2008; 10: R94. 
[60] Kinloch A, Lundberg K, Wait R, et al. Synovial fluid is a site of 
citrullination of autoantigens in inflammatory arthritis. Arthritis 
Rheum 2008; 58: 2287-95. 
[61] Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, 
Ronnelid J. Rheumatoid factor and antibodies to cyclic citrullinated 
peptides are associated with severe extra-articular manifestations in 
rheumatoid arthritis. Ann Rheum Dis 2007; 66: 59-64. 
[62] Stastny P. Association of the B-cell alloantigen DRw4 with rheu-
matoid arthritis. N Engl J Med 1978; 298: 869-71. 
[63] Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J 
Clin Invest 1976; 57: 1148-57. 
[64] Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, 
Criswell LA. Impact of shared epitope genotype and ethnicity on 
erosive disease; a meta-analysis of 3,240 rheumatoid arthritis pa-
tients. Arthritis Rheum 2004; 50: 400-12. 
[65] Gregersen PK, Silver J, Winchester RJ. The shared epitope hy-
pothesis. An approach to understanding the molecular genetics of 
susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 
1205-13. 
[66] Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. 
Cutting edge; the conversion of arginine to citrulline allows for a 
high-affinity peptide interaction with the rheumatoid arthritis-
associated HLA-DRB1*0401 MHC class II molecule. J Immunol 
2003; 171: 538-41. 
[67] Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining 
the complex rheumatoid arthritis phenotype based on specificity of 
the HLA-DRB1 shared epitope for antibodies to citrullinated pro-
teins. Arthritis Rheum 2005; 52: 3433-8. 
[68] Ding B, Padyukov L, Lundstrom E, et al. Different patterns of 
associations with anti-citrullinated protein antibody-positive and 
anti-citrullinated protein antibody-negative rheumatoid arthritis in 
the extended major histocompatibility complex region. Arthritis 
Rheum 2009; 60: 30-8. 
[69] Alizadeh BZ, Valdigem G, Coenen MJ, et al. Association analysis 
of functional variants of the FcgRIIa and FcgRIIIa genes with type 
1 diabetes, celiac disease and rheumatoid arthritis. Hum Mol Genet 
2007; 16: 2552-9. 
[70] Lee YH, Ji JD, Song GG. Associations between FCGR3A poly-
morphisms and susceptibility to rheumatoid arthritis; a metaanaly-
sis. J Rheumatol 2008; 35: 2129-35. 
[71] Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of 
human Fcgamma receptors and their polymorphic variants for hu-
man IgG subclasses. Blood 2009; 113: 3716-25. 
[72] Radstake TR, Franke B, Wenink MH, et al. The functional variant 
of the inhibitory Fcgamma receptor IIb (CD32B) is associated with 
the rate of radiologic joint damage and dendritic cell function in 
rheumatoid arthritis. Arthritis Rheum 2006; 54: 3828-37. 
[73] Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, et al. Association 
of interferon regulatory factor 5 haplotypes, similar to that found in 
systemic lupus erythematosus, in a large subgroup of patients with 
rheumatoid arthritis. Arthritis Rheum 2008; 58: 1264-74. 
[74] Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of 
rheumatoid arthritis and systemic lupus erythematosus. N Engl J 
Med 2007; 357: 977-86. 
[75] Radstake TR, Franke B, Hanssen S, et al. The Toll-like receptor 4 
Asp299Gly functional variant is associated with decreased rheuma-
toid arthritis disease susceptibility but does not influence disease 
severity and/or outcome. Arthritis Rheum 2004; 50: 999-1001. 
[76] Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, Martin 
J. Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid 
arthritis and systemic lupus erythematosus. Tissue Antigens 2004; 
63: 54-7. 
[77] Radstake TR, Roelofs MF, Jenniskens YM, et al. Expression of 
toll-like receptors 2 and 4 in rheumatoid synovial tissue and regula-
tion by proinflammatory cytokines interleukin-12 and interleukin-
18 via interferon-gamma. Arthritis Rheum 2004; 50: 3856-65. 
[78] Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released 
from necrotic synovial fluid cells activates rheumatoid arthritis 
synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005; 
52: 2656-65. 
[79] Ospelt C, Brentano F, Rengel Y, et al. Overexpression of toll-like 
receptors 3 and 4 in synovial tissue from patients with early rheu-
matoid arthritis; toll-like receptor expression in early and long-
standing arthritis. Arthritis Rheum 2008; 58: 3684-92. 
[80] Pierer M, Rethage J, Seibl R, et al. Chemokine secretion of rheu-
matoid arthritis synovial fibroblasts stimulated by Toll-like recep-
tor 2 ligands. J Immunol 2004; 172: 1256-65. 
[81] Vabulas RM, Ahmad-Nejad P, da Costa C, et al. Endocytosed 
HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the 
toll/interleukin-1 receptor signaling pathway in innate immune 
cells. J Biol Chem 2001; 276: 31332-9. 
[82] Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of 
Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp 
Med 2002; 195: 99-111. 
[83] Okamura Y, Watari M, Jerud ES, et al. The extra domain A of 
fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 
10229-33. 
Role of Antigen-Presenting Cells in Autoimmunity The Open Arthritis Journal, 2010, Volume 3    45 
[84] Clavel C, Nogueira L, Laurent L, et al. Induction of macrophage 
secretion of tumor necrosis factor alpha through Fcgamma receptor 
IIa engagement by rheumatoid arthritis-specific autoantibodies to 
citrullinated proteins complexed with fibrinogen. Arthritis Rheum 
2008; 58: 678-88. 
[85] van Venrooij WJ, Pruijn GJ. An important step towards completing 
the rheumatoid arthritis cycle. Arthritis Res Ther 2008; 10: 117. 
[86] Mathsson L, Lampa J, Mullazehi M, Ronnelid J. Immune com-
plexes from rheumatoid arthritis synovial fluid induce Fcgam-
maRIIa dependent and rheumatoid factor correlated production of 
tumour necrosis factor-alpha by peripheral blood mononuclear 
cells. Arthritis Res Ther 2006; 8: R64. 
[87] Sacre SM, Lo A, Gregory B, et al. Inhibitors of TLR8 reduce TNF 
production from human rheumatoid synovial membrane cultures. J 
Immunol 2008; 181: 8002-9. 
[88] van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. 
Rheumatoid arthritis subtypes identified by genomic profiling of 
peripheral blood cells; assignment of a type I interferon signature in 
a subpopulation of patients. Ann Rheum Dis 2007; 66: 1008-14. 
[89] Icen M, Nicola PJ, Maradit-Kremers H, et al. Systemic lupus 
erythematosus features in rheumatoid arthritis and their effect on 
overall mortality. J Rheumatol 2009; 36: 50-7. 
[90] Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. 
Cross-regulation of TNF and IFN-alpha in autoimmune diseases. 
Proc Natl Acad Sci USA 2005; 102: 3372-7. 
[91] Stokes MB, Foster K, Markowitz GS, et al. Development of glome-
rulonephritis during anti-TNF-alpha therapy for rheumatoid arthri-
tis. Nephrol Dial Transplant 2005; 20: 1400-6. 
[92] Blom AB, Radstake TR, Holthuysen AE, et al. Increased expres-
sion of Fcgamma receptors II and III on macrophages of rheuma-
toid arthritis patients results in higher production of tumor necrosis 
factor alpha and matrix metalloproteinase. Arthritis Rheum 2003; 
48: 1002-14. 
[93] Radstake TR, Blom AB, Sloetjes AW, et al. Increased Fcgam-
maRII expression and aberrant tumour necrosis factor alpha pro-
duction by mature dendritic cells from patients with active rheuma-
toid arthritis. Ann Rheum Dis 2004; 63: 1556-63. 
[94] Zhang Y, Liu S, Liu J, et al. Immune complex/Ig negatively regu-
late TLR4-triggered inflammatory response in macrophages 
through Fc gamma RIIb-dependent PGE2 production. J Immunol 
2009; 182: 554-62. 
[95] Blom AB, van Lent PL, van Vuuren H, et al. Fc gamma R expres-
sion on macrophages is related to severity and chronicity of syno-
vial inflammation and cartilage destruction during experimental 
immune-complex-mediated arthritis (ICA). Arthritis Res 2000; 2: 
489-503. 
[96] van Lent PL, van Vuuren AJ, Blom AB, et al. Role of Fc receptor 
gamma chain in inflammation and cartilage damage during experi-
mental antigen-induced arthritis. Arthritis Rheum 2000; 43: 740-
52. 
[97] van Lent PL, Nabbe K, Blom AB, et al. Role of activatory Fc 
gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in in-
flammation and cartilage destruction during experimental antigen-
induced arthritis. Am J Pathol 2001; 159: 2309-20. 
[98] Nabbe KC, van Lent PL, Holthuysen AE, Kolls JK, Verbeek S, van 
den Berg WB. FcgammaRI up-regulation induced by local adeno-
viral-mediated interferon-gamma production aggravates chondro-
cyte death during immune complex-mediated arthritis. Am J Pathol 
2003; 163: 743-52. 
[99] Diaz de Stahl T, Andren M, Martinsson P, Verbeek JS, Kleinau S. 
Expression of FcgammaRIII is required for development of colla-
gen-induced arthritis. Eur J Immunol 2002; 32: 2915-22. 
[100] Pine PR, Chang B, Schoettler N, et al. Inflammation and bone 
erosion are suppressed in models of rheumatoid arthritis following 
treatment with a novel Syk inhibitor. Clin Immunol 2007; 124: 
244-57. 
[101] Yuasa T, Kubo S, Yoshino T, et al. Deletion of fcgamma receptor 
IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J 
Exp Med 1999; 189: 187-94. 
[102] van Lent P, Nabbe KC, Boross P, et al. The inhibitory receptor 
FcgammaRII reduces joint inflammation and destruction in ex-
perimental immune complex-mediated arthritides not only by inhi-
bition of FcgammaRI/III but also by efficient clearance and endo-
cytosis of immune complexes. Am J Pathol 2003; 163: 1839-48. 
[103] Pietersz GA, Mottram PL, van de Velde NC, et al. Inhibition of 
destructive autoimmune arthritis in FcgammaRIIa transgenic mice 
by small chemical entities. Immunol Cell Biol 2009; 87: 3-12. 
[104] Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, et al. Inhibition of 
Toll-like receptor 4 breaks the inflammatory loop in autoimmune 
destructive arthritis. Arthritis Rheum 2007; 56: 2957-67. 
[105] Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A. 
Intra-articularly localized bacterial DNA containing CpG motifs 
induces arthritis. Nat Med 1999; 5: 702-5. 
[106] Liu ZQ, Deng GM, Foster S, Tarkowski A. Staphylococcal pepti-
doglycans induce arthritis. Arthritis Res 2001; 3: 375-80. 
[107] Zare F, Bokarewa M, Nenonen N, et al. Arthritogenic properties of 
double-stranded (viral) RNA. J Immunol 2004; 172: 5656-63. 
[108] Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy 
B, Flipo RM. Lack of efficacy of a third tumour necrosis factor al-
pha antagonist after failure of a soluble receptor and a monoclonal 
antibody. Rheumatology (Oxford) 2006; 45: 1121-4. 
[109] Iannone F, Trotta F, Montecucco C, et al. Etanercept maintains the 
clinical benefit achieved by infliximab in patients with rheumatoid 
arthritis who discontinued infliximab because of side effects. Ann 
Rheum Dis 2007; 66: 249-52. 
[110] Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year 
followup study of patients with rheumatoid arthritis who received a 
combination of abatacept and methotrexate. Arthritis Rheum 2008; 
58: 953-63. 
[111] Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheuma-
toid arthritis refractory to tumor necrosis factor alpha inhibition. N 
Engl J Med 2005; 353: 1114-23. 
[112] Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of 
the selective co-stimulation modulator abatacept following 2 years 
of treatment in patients with rheumatoid arthritis and an inadequate 
response to anti-tumour necrosis factor therapy. Ann Rheum Dis 
2008; 67: 547-54. 
[113] O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid 
arthritis with methotrexate alone, sulfasalazine and hydroxychloro-
quine, or a combination of all three medications. N Engl J Med 
1996; 334: 1287-91. 
[114] O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthri-
tis with methotrexate and hydroxychloroquine, methotrexate and 
sulfasalazine, or a combination of the three medications; results of 
a two-year, randomized, double-blind, placebo-controlled trial.  
Arthritis Rheum 2002; 46: 1164-70. 
[115] Calguneri M, Pay S, Caliskaner Z, et al. Combination therapy 
versus monotherapy for the treatment of patients with rheumatoid 
arthritis. Clin Exp Rheumatol 1999; 17: 699-704. 
[116] Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of 
combination therapy with single-drug therapy in early rheumatoid 
arthritis; a randomised trial. FIN-RACo Trial Group. Lancet 1999; 
353: 1568-73. 
[117] Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with 
methotrexate and hydroxychloroquine for rheumatoid arthritis in-
creases exposure to methotrexate. J Rheumatol 2002; 29: 2077-83. 
[118] Vanags D, Williams B, Johnson B, et al. Therapeutic efficacy and 
safety of chaperonin 10 in patients with rheumatoid arthritis; a 
double-blind randomised trial. Lancet 2006; 368: 855-63. 
[119] Akyol S, Gercel-Taylor C, Reynolds LC, Taylor DD. HSP-10 in 
ovarian cancer; expression and suppression of T-cell signaling. 
Gynecol Oncol 2006; 101: 481-6. 
[120] Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. 
Peptide receptor radionuclide therapy in vitro using [111In-
DTPA0]octreotide. J Nucl Med 2003; 44: 98-104. 
[121] Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of 
rheumatoid arthritis with a Syk kinase inhibitor; a twelve-week, 
randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 
3309-18. 
[122] Stephanie GY, Kong J, Cheema GS, Keen CL, Wick G, Gershwin 
ME. The immunobiology of systemic sclerosis. Semin Arthritis 
Rheum 2008; 38(2): 132-60. 
[123] Mayes MD, Lacey JV, Jr, Beebe-Dimmer J, et al. Prevalence, 
incidence, survival, and disease characteristics of systemic sclerosis 
in a large US population. Arthritis Rheum 2003; 48: 2246-55. 
[124] Mayes MD, Trojanowska M. Genetic factors in systemic sclerosis. 
Arthritis Res Ther 2007; 9(Suppl 2): S5. 
[125] Zhou X, Tan FK, Wang N, et al. Genome-wide association study 
for regions of systemic sclerosis susceptibility in a Choctaw Indian 
population with high disease prevalence. Arthritis Rheum 2003; 48: 
2585-92. 
[126] Ahmed SS, Tan FK, Arnett FC. The complex genetics of 
scleroderma. Am J Med 2002; 112: 584-6. 
[127] Genth E, Mierau R, Genetzky P, et al. Immunogenetic associations 
of scleroderma-related antinuclear antibodies. Arthritis Rheum 
1990; 33: 657-65. 
[128] Morel PA, Chang HJ, Wilson JW, et al. Severe systemic sclerosis 
with anti-topoisomerase I antibodies is associated with an HLA-
DRw11 allele. Hum Immunol 1994; 40: 101-10. 
[129] Rands AL, Whyte J, Cox B, Hall ND, McHugh NJ. MHC class II 
associations with autoantibody and T cell immune responses to the 
46    The Open Arthritis Journal, 2010, Volume 3 Santegoets et al. 
scleroderma autoantigen topoisomerase I. J Autoimmun 2000; 15: 
451-8. 
[130] Dieude P, Guedj M, Wipff J, et al. Association between the IRF5 
rs2004640 functional polymorphism and systemic sclerosis; a new 
perspective for pulmonary fibrosis. Arthritis Rheum 2009; 60: 225-
33. 
[131] Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional 
variants of IFN regulatory factor 5 (IRF5) define risk and protec-
tive haplotypes for human lupus. Proc Natl Acad Sci USA 2007; 
104: 6758-63. 
[132] Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the 
genetic predisposition to systemic sclerosis phenotype. Hum Mol 
Genet 2009; 18: 2071-7. 
[133] Harvey GR, McHugh NJ. Serologic abnormalities in systemic 
sclerosis. Curr Opin Rheumatol 1999; 11: 495-502. 
[134] Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially 
regulated interferon gene expression and vasculotrophism in the pe-
ripheral blood cells of systemic sclerosis patients. Rheumatology 
(Oxford) 2006; 45: 694-702. 
[135] Duan H, Fleming J, Pritchard DK, et al. Combined analysis of 
monocyte and lymphocyte messenger RNA expression with serum 
protein profiles in patients with scleroderma. Arthritis Rheum 
2008; 58: 1465-74. 
[136] York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, 
Lafyatis R. A macrophage marker, Siglec-1, is increased on circu-
lating monocytes in patients with systemic sclerosis and induced by 
type I interferons and toll-like receptor agonists. Arthritis Rheum 
2007; 56: 1010-20. 
[137] Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by 
scleroderma sera containing autoantibodies to topoisomerase I:  
association of higher interferon-alpha activity with lung fibrosis.  
Arthritis Rheum 2008; 58: 2163-73. 
[138] Duncan MR, Berman B. Persistence of a reduced-collagen-
producing phenotype in cultured scleroderma fibroblasts after 
short-term exposure to interferons. J Clin Invest 1987; 79: 1318-24. 
[139] Coelho LF, de Oliveira JG, Kroon EG. Interferons and 
scleroderma-a new clue to understanding the pathogenesis of 
scleroderma? Immunol Lett 2008; 118: 110-5. 
[140] Fleming JN, Nash RA, Mahoney WM, Jr, Schwartz SM. Is 
scleroderma a vasculopathy? Curr Rheumatol Rep 2009; 11: 103-
10. 
[141] Boros P, Odin JA, Chen J, Unkeless JC. Specificity and class dis-
tribution of Fc gamma R-specific autoantibodies in patients with 
autoimmune disease. J Immunol 1994; 152: 302-6. 
[142] Davis K, Boros P, Keltz M, Unkeless JC, Fleischmajer R. Circulat-
ing Fc gamma receptor-specific autoantibodies in localized and 
systemic scleroderma. J Am Acad Dermatol 1995; 33: 612-6. 
[143] Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoanti-
bodies to the PDGF receptor in systemic sclerosis. N Engl J Med 
2006; 354: 2667-76. 
[144] Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of 
monocyte chemoattractant protein 1 in systemic sclerosis; role of 
platelet-derived growth factor and effects on monocyte chemotaxis 
and collagen synthesis. Arthritis Rheum 2001; 44: 2665-78. 
[145] Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. 
Chemokine expression by systemic sclerosis fibroblasts; abnormal 
regulation of monocyte chemoattractant protein 1 expression. 
Arthritis Rheum 2001; 44: 1382-6. 
[146] Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of 
monocyte chemoattractant protein-1 in the lesional skin of systemic 
sclerosis. J Dermatol Sci 2001; 26: 133-9. 
[147] Yamamoto T, Eckes B, Krieg T. High expression and autoinduc-
tion of monocyte chemoattractant protein-1 in scleroderma fibro-
blasts. Eur J Immunol 2001; 31: 2936-41. 
[148] Gharaee-Kermani M, McCullumsmith RE, Charo IF, Kunkel SL, 
Phan SH. CC-chemokine receptor 2 required for bleomycin-
induced pulmonary fibrosis. Cytokine 2003; 24: 266-76. 
[149] Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 
2008; 214: 199-210. 
[150] Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of 
patients with systemic sclerosis. J Rheumatol 1992; 19: 1202-6. 
[151] Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infil-
trates in clinically involved skin from patients with systemic scle-
rosis of recent onset predominantly consist of mono-
cytes/macrophages. Pathobiology 1995; 63: 48-56. 
[152] van de Water J, Haapanen L, Boyd R, Abplanalp H, Gershwin ME. 
Identification of T cells in early dermal lymphocytic infiltrates in 
avian scleroderma. Arthritis Rheum 1989; 32: 1031-40. 
[153] van de Water J, Gershwin ME, Abplanalp H, Wick G, von der 
Mark K. Serial observations and definition of mononuclear cell in-
filtrates in avian scleroderma, an inherited fibrotic disease of chick-
ens. Arthritis Rheum 1984; 27: 807-15. 
[154] Gentiletti J, McCloskey LJ, Artlett CM, Peters J, Jimenez SA, 
Christner PJ. Demonstration of autoimmunity in the tight skin-2 
mouse; a model for scleroderma. J Immunol 2005; 175: 2418-26. 
[155] Christner PJ, Peters J, Hawkins D, Siracusa LD, Jimenez SA. The 
tight skin 2 mouse. An animal model of scleroderma displaying cu-
taneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 
1995; 38: 1791-8. 
[156] Yamamoto T. The bleomycin-induced scleroderma model; what 
have we learned for scleroderma pathogenesis? Arch Dermatol Res 
2006; 297: 333-44. 
[157] Razonable RR, Henault M, Paya CV. Stimulation of toll-like recep-
tor 2 with bleomycin results in cellular activation and secretion of 
pro-inflammatory cytokines and chemokines. Toxicol Appl Phar-
macol 2006; 210: 181-9. 
[158] Yoshizaki A, Iwata Y, Komura K, et al. CD19 regulates skin and 
lung fibrosis via Toll-like receptor signaling in a model of bleomy-
cin-induced scleroderma. Am J Pathol 2008; 172: 1650-63. 
[159] Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immuno-
suppressive therapy and autologous hematopoietic cell transplanta-
tion for severe systemic sclerosis; long-term follow-up of the US 
multicenter pilot study. Blood 2007; 110: 1388-96. 
[160] van Laar JM, Stolk J, Tyndall A. Scleroderma lung; pathogenesis, 
evaluation and current therapy. Drugs 2007; 67: 985-96. 
[161] Reveille JD. Genetic studies in the rheumatic diseases; present 




Received: June 15, 2009 Revised: October 07, 2009 Accepted: October 29, 2009 
 
© Santegoets et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the 
work is properly cited.  
